The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE)
CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).
CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure.
CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.
CAPTIVATE includes multiple domains examining different therapies for CKD. Participants may enrol in one or more domains and domains will be added and closed over time. The platform operates under a core protocol with each domain described in a domain specific appendix.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Chronic kidney disease (CKD) affects over 800 million people globally and is projected to be the 5th most common cause of death by 2040. CKD progresses to kidney failure, increases the risk of early death, heart disease, and leads to a poorer quality of life.
Current treatments do not entirely remove the risk of kidney failure in people with CKD. To improve the outcomes of people with CKD, it is crucial to find the best treatment or combination of treatments that can slow CKD progression. CAPTIVATE aims to address this need.
CAPTIVATE has been designed to test multiple treatments within a common research platform. This design is more efficient and will lead to a shorter time for patients to receive effective treatments. The trial is 'eternal', which means that participants will continue to be recruited for many years until the trial is finally wound up. It is also 'adaptive', providing the flexibility to add new treatments, or remove those that are not working.
Participants can participate in more than one treatment at the same time or at different times. Participants receive each study treatment for 2 years. For each treatment, participants are followed up at study visits that occur at approximately one month, 3 months, 6 months, 12 months, 18 months and 2 years after starting treatment. A final study visit occurs one month after the end of the 2-year treatment phase. Information collected at study visits include blood and urine test results, safety assessments and treatment adherence. Information about the overall health status of each participant is collected every 5 years.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Enmoore Lin
- Phone Number: 61 2 8052 4511
- Email: captivate@georgeinstitute.org.au
Study Locations
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australia, 2605
- Recruiting
- The Canberra Hospital
-
Contact:
- Girish Talaulikar
-
-
New South Wales
-
Kingswood, New South Wales, Australia, 2747
- Recruiting
- Nepean Blue Mountains Local Health District
-
Contact:
- Bhadran Bose
-
Kogarah, New South Wales, Australia, 2217
- Recruiting
- St George Hospital
-
Contact:
- Sunil Badve
-
New Lambton Heights, New South Wales, Australia, 2305
- Recruiting
- John Hunter Hospital
-
Contact:
- Bobby Chacko
-
Westmead, New South Wales, Australia, 2145
- Recruiting
- Westmead Hospital
-
Contact:
- Vincent Lee
-
-
Queensland
-
Birtinya, Queensland, Australia, 4575
- Recruiting
- Sunshine Coast Hospital and Health Service
-
Contact:
- Nicholas Gray
-
Douglas, Queensland, Australia, 4814
- Recruiting
- Townsville University Hospital
-
Contact:
- Vikas Srivastava
-
Ipswich, Queensland, Australia, 4305
- Recruiting
- West Moreton Hospital & Health Service
-
Contact:
- Sree Venuthurupalli
-
Southport, Queensland, Australia, 4215
- Recruiting
- Gold Coast Hospital and Health Service
-
Contact:
- Jagadeesh Kurtkoti
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Recruiting
- Royal Adelaide
-
Contact:
- Michael Collins
-
Elizabeth Vale, South Australia, Australia, 5112
- Recruiting
- Lyell McEwin Hospital
-
Contact:
- Nitesh Rao
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Recruiting
- Austin Health
-
Contact:
- Sharon Ford
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- Recruiting
- South Metropolitan Health Service, Fiona Stanley Hospital
-
Contact:
- Suda Swaminathan
-
-
-
-
-
Dehradun, India, 248001
- Not yet recruiting
- Max Superspeciality Hospital, Dehradun
-
Contact:
- Puneet Arora
-
Ghaziabad, India, 201012
- Recruiting
- Max Superspecialty Hospital, Ghaziabad
-
Contact:
- Manoj Kumar Singhal
-
Puducherry, India, 607403
- Recruiting
- Aarupadai Veedu Medical College & Hospital (AVMCH), Puducherry
-
Contact:
- Venkatesh A
-
-
Andhra Pradesh
-
Visakhapatnam, Andhra Pradesh, India, 530045
- Recruiting
- Gitam Institute of Medical Sciences and Research
-
Contact:
- Murty Mandapaka
-
-
Bihar
-
Patna, Bihar, India, 800001
- Recruiting
- Patna Medical College and Hospital
-
Contact:
- Harsh Vardhan
-
-
Chhattisgarh
-
Raipur, Chhattisgarh, India, 492002
- Recruiting
- DKS Super Speciality Hospital, Raipur
-
Contact:
- Varun Agrawal
-
-
Dehradun
-
Dehradun, Dehradun, India, 248001
- Recruiting
- Mysore Medical College
-
Contact:
- Puneet Arora
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380025
- Recruiting
- GCS Medical College, Hospital & Research Centre
-
Contact:
- Suvika Patel
-
Vadodara, Gujarat, India, 390007
- Recruiting
- Aman Hospital & Research Center Vadodara
-
Contact:
- Aman Khanna
-
-
Karnataka
-
Mangaluru, Karnataka, India, 575002
- Recruiting
- Father Muller Medical College Hospital
-
Contact:
- Manjunath Kulkarni
-
-
Kerala
-
Meppādi, Kerala, India, 673511
- Recruiting
- Dr Moopen's Medical College
-
Contact:
- Aneesh Basheer
-
-
Madhya Pradesh
-
Indore, Madhya Pradesh, India
- Recruiting
- CARE-CHL Hospital
-
Contact:
- Isha Tiiwari
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, India, 600024
- Recruiting
- Medway Hospital
-
Contact:
- Shivakumar Dakshinamoorthy
-
-
Telangana
-
Hyderabad, Telangana, India, 500084
- Recruiting
- Yashoda Hospital Hitec City
-
Contact:
- Mahesh Kota
-
Hyderabad, Telangana, India
- Recruiting
- Apollo Hospitals
-
Contact:
- Haresh Patel
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, India, 226003
- Recruiting
- Charak Hospital and Research Centre
-
Contact:
- Sakshi Jain
-
-
Uttarakhand
-
Dehradun, Uttarakhand, India, 248001
- Recruiting
- Shri Guru Ram Rai Medical College and Shri Mahant Indiresh Hospital
-
Contact:
- Gaurav Shekhar Sharma
-
-
West Bengal
-
Kolkata, West Bengal, India, 700107
- Recruiting
- Fortis Hospital
-
Contact:
- Upal Sengupta
-
Siliguri, West Bengal, India, 734012
- Recruiting
- North Bengal Medical College & Hospital
-
Contact:
- Arpita Ray Chaudhury
-
-
-
-
-
Auckland, New Zealand, 1023
- Recruiting
- Auckland City Hospital
-
Contact:
- Dr Helen Pilmore
-
Auckland, New Zealand, 2025
- Recruiting
- Aotearoa Clinical Trials Trust, Middlemore Hospital
-
Contact:
- Kalpa Jayanatha
-
Auckland, New Zealand, 0620
- Recruiting
- Health New Zealand, Te Whatu Ora Waitemata, North Shore Hospital
-
Contact:
- Ashik Hayat
-
Dunedin, New Zealand, 9016
- Recruiting
- 201 Great King Street, Central Dunedin, Dunedin 9016, New Zealand
-
Contact:
- John Schollum
-
Palmerston North, New Zealand, 4442
- Recruiting
- Midcentral - Palmerston North Hospital
-
Contact:
- Dr Curtis Walker
-
Whangarei, New Zealand, 0148
- Recruiting
- Private Bag 9742 Maunu Road, Horahora, Whangārei 0148, New Zealand
-
Contact:
- Adam Mullan
-
-
Hawkes Bay
-
Hastings, Hawkes Bay, New Zealand, 4120
- Recruiting
- Health New Zealand, Te Whatu Ora Te Matau a Maui, Hawke's Bay Hospital
-
Contact:
- Hussain Allawati
-
-
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Active, not recruiting
- Hospital Germans Trias i Pujol
-
Horta-Guinardó, Barcelona, Spain, 08035
- Recruiting
- Vall d'Hebron University Hospital
-
Contact:
- Dr Maria Jose Soler Romeo
-
-
Espana
-
Valencia, Espana, Spain, 46010
- Recruiting
- Hospital Clinico Universitario València (INCLIVA)
-
Contact:
- Prof Jose Luis Gorriz Teruel
-
-
-
-
-
Colombo, Sri Lanka, 00700
- Recruiting
- National Hospital of Sri Lanka
-
Contact:
- Dr Mathu Selvarajah
-
Kandy, Sri Lanka, 20000
- Recruiting
- Kandy National Hospital
-
Contact:
- Dr Nishantha Nanayakkara
-
Kurunegala, Sri Lanka
- Recruiting
- Kurunegala Teaching Hospital
-
Contact:
- Dr Premil Rajakrishnan
-
Nugegoda, Sri Lanka, 10250
- Recruiting
- Sri Jayewardenepura General Hospital
-
Contact:
- Dr Harshani Perera
-
Peradeniya, Sri Lanka, 20400
- Recruiting
- Peradeniya Teaching Hospital
-
Contact:
- Dr Rajitha Abeysekera
-
Ragama, Sri Lanka, 11010
- Recruiting
- Colombo North Teaching Hospital
-
Contact:
- Dr Nalaka Herath
-
-
Northern Province
-
Jaffna, Northern Province, Sri Lanka, 4000
- Recruiting
- Jaffna Teaching Hospital
-
Contact:
- Dr. Brammah Thangarajah
-
-
Polonnaruwa
-
Colombo, Polonnaruwa, Sri Lanka, 51000
- Recruiting
- National Nephrology Specialized Hospital
-
Contact:
- Dr Naseef Thaseem
-
-
Western Province
-
Dehiwala, Western Province, Sri Lanka, 10290
- Recruiting
- University Hospital, Kotelawala Defence University
-
Contact:
- Dr Dilukshi Pilapitiya
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years
- Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m2)
- Currently receiving standard of care treatment according to treating physician
- Eligible for randomisation in at least one recruiting domain-specific appendix
- Participant and treating physician are willing and able to perform trial procedures
Exclusion Criteria:
- Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months
- Life expectancy less than 6 months
To be included in any of the following DOMAINS the participant must met eligible for the PLATFORM (as listed above)
MRA domain
Inclusion Criteria:
- Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine protein-creatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
- On a stable standard of care treatment for CKD, including a SGLT2i unless there is a documented reason not to be using a SGLT2i*, for 4 weeks before screening according to treating physician.
- Treating physician believes finerenone is clinically appropriate for the participant.
- Participant and treating physician are willing and able to perform MRA DSA procedures.
- Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any MRA DSA related procedures
Exclusion Criteria:
- Recipient of kidney transplant
- Hyperkalaemia (serum potassium ≥5.0 mmol/L) at time of screening
- Current treatment with MRA, where the treating physician or patient is not willing to discontinue this medication. If willing to discontinue the MRA, the potential participant must be re-screened after they have been on stable standard of care treatment for 4 weeks without the MRA.
- Known allergy, intolerance or contraindication to MRAs
- Current treatment with strong CYP3A4 inhibitors
- Systolic BP <110 mmHg or diastolic BP<55 mmHg without antihypertensive therapy at time of screening
- Severe hepatic impairment (defined as Child-Pugh Class C)
- Adrenal insufficiency
- Currently pregnant or breast feeding, or intending to become pregnant
GLP-1 RA Domain
Inclusion Criteria
- Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine proteincreatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
- On a stable standard of care treatment for CKD, including a SGLT2i and maximum tolerated ACEi/ARB unless there is a documented reason not to be using a SGLT2i, for 4 weeks before screening.
- HbA1c less than or equal to 10% (less than or equal to 86mmol/L)
- BMI ≥23 kg/m2 and < 50 kg/m2
- Treating physician believes semaglutide is clinically appropriate for the participant
- Participant and treating physician are willing and able to perform GLP-1 RA DSA procedures
- Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any GLP-1 RA DSA related procedures
Exclusion Criteria
- Recipient of kidney transplant
- Major adverse cardiovascular events (MACE), consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, within 90 days prior to the day of screening
- Presently classified as being in New York Heart Association (NYHA) Class IV heart failure
- Personal or first-degree relative(s) with a history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC)
- Previous episode of pancreatitis
- Uncontrolled thyroid disease TSH>6.0 mIU/L or <0.4mlU/L
- Type 1 diabetes
- Current treatment with a GLP-1 RA, where it is in the participant's best interests to continue the GLP-1 RA or where the treating physician or patient is not willing to discontinue this medication for a minimum of 4 weeks prior to randomisation and for the full duration of the trial (ie. 108 weeks if assigned to placebo).
- Known allergy, intolerance, or contraindication to GLP-1 RAs
- Currently pregnant or breast feeding, or intending to become pregnant or is of child-bearing potential, and not using a highly effective contraceptive method
- Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Finerenone
Finerenone 10mg or 20mg tablets |
Finerenone 10mg or 20mg tablets, oral, once daily
Other Names:
|
|
Placebo Comparator: Placebo Finerenone
Finerenone matched placebo tablets |
Finerenone matched placebo tablets, oral, once daily |
|
Experimental: Semaglutide
Semaglutide 1.0 mg or 2.4 mg pen injector |
Semaglutide 1.0mg or 2.4mg pen injector, subcutaneous injection, once weekly |
|
Placebo Comparator: Placebo Semaglutide
Semaglutide matched placebo pen injector |
Semaglutide matched pen injector, subcutaneous injection, once weekly |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Core Primary Outcome Measure
Time Frame: From randomisation to week 108
|
The primary outcome is chronic eGFR slope. Chronic eGFR slope measures the rate of eGFR decline while on treatment. The duration of time over which chronic eGFR slope is computed can vary by domain and is determined by clinical considerations such as whether the investigational product can cause an acute decline in eGFR upon initiation. DSAs will specify the duration of time over which chronic eGFR slope is computed for the individual domain. |
From randomisation to week 108
|
|
MRA Domain Primary Outcome Measure
Time Frame: From week 4 to week 108
|
Chronic eGFR slope estimated from all available eGFR values from week 4 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment. |
From week 4 to week 108
|
|
GLP1-RA Domain Primary Outcome Measure
Time Frame: From week 0 to week 108
|
Chronic eGFR slope estimated from all available eGFR values from Week 0 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment. |
From week 0 to week 108
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Core Protocol Secondary outcomes
Time Frame: week 0 and 24 weeks
|
1. Change in albuminuria as measured by uACR (or uPCR if uACR unavailable) between week 0 and 24 weeks, measured as a continuous variable. |
week 0 and 24 weeks
|
|
Core Protocol Secondary outcomes
Time Frame: week 0 to end of washout
|
2. eGFR slope from week 0 to end of washout |
week 0 to end of washout
|
|
Core Protocol Secondary outcomes
Time Frame: week 0 to end of washout
|
3. Change in eGFR from week 0 to end of washout |
week 0 to end of washout
|
|
Core Protocol Secondary outcomes
Time Frame: between week 0 and 108 weeks
|
4. Composite outcome of proportion of participants experiencing a ≥40% eGFR decline between week 0 and 108 weeks, and proportion of participants developing kidney failure (defined as eGFR <15 mL/min/1.73m2 or chronic kidney replacement therapy start†) at 108 weeks. |
between week 0 and 108 weeks
|
|
Core Protocol Secondary outcomes
Time Frame: from start of study drug (week 0) to washout (week 108) or kidney failure
|
5. Time to a composite outcome of ≥40% eGFR decline from week 0 or kidney failure |
from start of study drug (week 0) to washout (week 108) or kidney failure
|
|
Core Protocol Secondary outcomes
Time Frame: at 108 weeks
|
6. All-cause mortality at 108 weeks |
at 108 weeks
|
|
Core Protocol Secondary outcomes
Time Frame: between week 0 and week 108
|
7. Proportion of participants experiencing one or more cardiovascular events (cardiovascular death, hospitalised heart failure, myocardial infarction, stroke)* between week 0 and week 108 |
between week 0 and week 108
|
|
Core Protocol Secondary outcomes
Time Frame: from start of study drug (week 0) to end of washout (week 108)
|
8. Time to first occurrence of a cardiovascular event |
from start of study drug (week 0) to end of washout (week 108)
|
|
Core Protocol Secondary outcomes
Time Frame: from start of study drug (week 0) to end of treatment (up to week 104)
|
9. Safety and tolerability of treatment |
from start of study drug (week 0) to end of treatment (up to week 104)
|
|
Core Protocol Secondary outcomes
Time Frame: 6-monthly intervals from randomisation to week 108
|
10. Change in quality of life measured using the Quality of Life Impact Survey for Kidney Disease (QDISCKD) at 6-monthly intervals from randomisation to week 108. |
6-monthly intervals from randomisation to week 108
|
|
MRA Domain Secondary Outcome
Time Frame: from start of study drug (week 0) to end of washout (week 108)
|
MRA DSA has a domain-specific secondary outcome that evaluates the time to the composite of ≥57% eGFR decline from week 0 or kidney failure |
from start of study drug (week 0) to end of washout (week 108)
|
|
GLP-1 RA Domain Secondary Outcome
Time Frame: from start of study drug (week 0) to end of washout (week 108)
|
1. Change in eGFR slope from Week 0 to Week 108. |
from start of study drug (week 0) to end of washout (week 108)
|
|
GLP-1 RA Domain Secondary Outcome
Time Frame: from start of study drug (week 0) to end of washout (week 108)
|
2. Time to composite of onset of kidney failure (initiation of long-term dialysis, kidney transplantation, or a reduction in the eGFR to <15 mL per minute per 1.73 m2 sustained for ≥28 days), a sustained (for ≥28 days) 50% or greater reduction in eGFR from Week 0, or death from kidney-related or cardiovascular causes. |
from start of study drug (week 0) to end of washout (week 108)
|
|
GLP-1 RA Domain Secondary Outcome
Time Frame: from Week 0 to Week 108
|
3. Time to first occurrence of onset of persistent ≥50% reduction in eGFR from Week 0 to Week 108 |
from Week 0 to Week 108
|
|
GLP-1 RA Domain Secondary Outcome
Time Frame: from start of study drug (week 0) to end of washout (week 108)
|
4. Time to first occurrence of a composite outcome of major adverse cardiovascular events (MACE) consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death |
from start of study drug (week 0) to end of washout (week 108)
|
|
GLP-1 RA Domain Secondary Outcome
Time Frame: from start of study drug (week 0) to end of washout (week 108)
|
5. Time to occurrence of all-cause death |
from start of study drug (week 0) to end of washout (week 108)
|
|
GLP-1 RA Domain Secondary Outcome
Time Frame: from Week 0 to Week 108
|
6. Change in body weight from Week 0 to Week 108 |
from Week 0 to Week 108
|
|
GLP-1 RA Domain Secondary Outcome
Time Frame: Week 0 to Week 108
|
7. Change in HbA1c from Week 0 to Week 108 |
Week 0 to Week 108
|
|
GLP-1 RA Domain Secondary Outcome
Time Frame: from Week 0 to Week 108
|
8. Change in systolic blood/diastolic blood pressure from Week 0 to Week 108 |
from Week 0 to Week 108
|
|
GLP-1 RA Domain Secondary Outcome
Time Frame: from Week 0 to Week 108
|
9. Change in NT-proBNP from Week 0 to Week 108 |
from Week 0 to Week 108
|
|
GLP-1 RA Domain Secondary Outcome
Time Frame: from randomisation to Week 108
|
10. Change in health status measured using the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ) at 6-monthly intervals from randomisation to Week 108 |
from randomisation to Week 108
|
|
GLP-1 RA Domain Secondary Outcome
Time Frame: Week 0 to end of trial
|
11. Incidence of AEs and the following medical events of special interest (MESI) from Week 0 to end of trial:
|
Week 0 to end of trial
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Sradha Kotwal, The George Institute
- Study Chair: Hiddo Lambers Heerspink, The George Institute
Publications and helpful links
General Publications
- Kotwal SS, Perkovic V, Jardine MJ, Kim D, Shah NA, Lin E, Coggan S, Billot L, Vart P, Wheeler DC, de Boer IH, Zhang H, Hou FF, Sugawara Y, Marion J, Lewis RJ, Berry LR, McGlothlin A, Jha V, De Nicola L, Gorriz JL, Heerspink HJL; GKPTN and CAPTIVATE Investigators. The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol. JAMA Netw Open. 2024 Dec 2;7(12):e2449998. doi: 10.1001/jamanetworkopen.2024.49998.
- Heerspink HJL, Kretzler M. Clinical Trials for Kidney Disease in the Era of Personalized Medicine. J Am Soc Nephrol. 2024 Aug 1;35(8):1123-1126. doi: 10.1681/ASN.0000000000000412. Epub 2024 May 9. No abstract available.
- Yeung EK, Rangaswami J, Tuttle KR, Grams ME, Tangri N, Vaduganathan M, Neuen BL. A Framework for Risk-Based Implementation of Combination Therapy in CKD: Who, Why, When, and How? Clin J Am Soc Nephrol. 2026 Jun 23. doi: 10.2215/CJN.0000001158. Online ahead of print.
- Shah NA, Du R, Neuen BL, Levin A, Jha V, Heerspink HJL, Kotwal SS; CAPTIVATE investigators. A Dose of Perspective: A Multinational Survey of Patient and Clinician Views on Combination Therapy in CKD. Kidney360. 2026 Aug 1;7(8):1772-1780. doi: 10.34067/KID.0000001227. Epub 2026 Jun 2.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Renal Insufficiency
- Pathological Conditions, Signs and Symptoms
- Renal Insufficiency, Chronic
- semaglutide
- finerenone
Other Study ID Numbers
Other Study ID Numbers
- P01351
- U1111-1324-3113 (Other Identifier: World Health Organisation, Universal Trial Number (UTN))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Trial data will be made available as a resource for future unspecified research, subject to any prior contractual obligations. Researchers wishing to gain access to the study resources will be required to submit an application for review by the Platform Oversight Committee, including a detailed project description, a list of data requested, and evidence of ethical approval. De-identified data extracts will be made available to approved proposals, and will not include data obtained from data linkage with local registries.
IPD Sharing Time Frame
TBC
IPD Sharing Access Criteria
Assessments of data requests will be based on sound science, benefit-risk balancing and research team expertise.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.